Sort
48,018 grants matching “immunotherapy”
The nose-lung cross talk in upper respiratory virus infection induced asthma exacerbations
$596,182Xiaoyang Hua · University Of Iowa · R01 · FY2024 · HL
Role of Gut Microbiota in Modulating Immune Checkpoint Inhibitory Therapy for Cancer
$596,098Andrew Y Koh · Ut Southwestern Medical Center · R01 · FY2021 · CA
Role of Gut Microbiota in Modulating Immune Checkpoint Inhibitory Therapy for Cancer
$596,098Andrew Y Koh · Ut Southwestern Medical Center · R01 · FY2020 · CA
NANO2 ENHANCES IMMUNOTHERAPY IN TRIPLE NEGATIVE BREAST CANCERS
$596,089George Washington University (The) · · FY2022 · Defense Health Agency
Designer Cytokine Therapy of Hepatocellular Carcinoma
$596,066Paul B Fisher · Virginia Commonwealth University · P01 · FY2024 · CA
Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC
$596,039John V. Heymach · University Of Tx Md Anderson Can Ctr · U01 · FY2018 · CA
OPTIMAL TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS
$596,003State University New York Stony Brook · U01 · FY2003 · DK
Bottlebrush polymer prodrugs for targeted delivery of combination therapies and in vivo imaging of pharmacological response
$595,926Jeremiah Allen Johnson · Massachusetts Institute Of Technology · R01 · FY2025 · CA
Predictive and Diagnostic Radiomic Signatures in Non-Small Cell Lung Cancer (NSCLC) on Immunotherapy
$595,875Despina Kontos · University Of Pennsylvania · R01 · FY2023 · CA
TRANSLATING NK CELL BIOLOGY INTO CLINICAL CANCER IMMUNOTHERAPY
$595,787Todd A Fehniger · Washington University · R01 · FY2019 · CA
Immunotherapy for Malignant Mesothelioma
$595,766Raffit Hassan · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA
VLA-4âtargeted 67Cu-LLP2A preconditioning enhances efficacy of T-cell-based adoptive immunotherapy
$595,764Ravi Bhasker Patel · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · CA
Characterization of high-grade serous ovarian cancer subtypes via single-cell profiling
$595,702Casey S Greene · University Of Pennsylvania · R01 · FY2020 · CA
Engineering immunotherapeutic probiotics to mitigate irAE
$595,682Tal Danino · Columbia Univ New York Morningside · U01 · FY2021 · CA
Cardioprotective Therapy for Doxorubicin Using iPSC Microtissue and CRISPR Screening
$595,679Joseph C Wu · Stanford University · R01 · FY2023 · HL
Nano and biomolecular engineered technologies for neoantigen-specific T cell capture and characterization
$595,609James R. Heath · Institute For Systems Biology · R01 · FY2021 · CA
Reprogramming the Tumor Immune Microenvironment with Chemokines to Potentiate Immune Oncology Treatments in Oral Cancer
$595,600J. Silvio Gutkind · University Of California, San Diego · R01 · FY2024 · DE
Role of neurokinin 1 receptor signaling in keratinocytes in allergic contact dermatitis
$595,577Adriana T Larregina · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · AI
Role of neurokinin 1 receptor signaling in keratinocytes in allergic contact dermatitis
$595,577Adriana T Larregina · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · AI
Role of neurokinin 1 receptor signaling in keratinocytes in allergic contact dermatitis
$595,577Adriana T Larregina · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · AI
Elucidating the Immune Suppressive Mechanism of SIGLEC-15 in the Tumor Microenvironment
$595,576Jun Wang · New York University School Of Medicine · R01 · FY2023 · CA
An urinary drug disposing approach for treatment of bladder Cancer
$595,483Benedict Shek Hang Law · Weill Medical Coll Of Cornell Univ · R01 · FY2024 · CA
Oral microbiome and inflammatory status in antimicrobially-treated oral cancer patients
$595,456Yvonne L Kapila · University Of California Los Angeles · R01 · FY2024 · CA
"Off-the-Shelf" iPSC-Derived Regulatory T Cell Immunotherapeutics
$595,443Bruce R. Blazar · University Of Minnesota · P01 · FY2023 · CA
Mouse models of Kras-mutant colorectal cancer
$595,434Kevin Michael Haigis · Dana-Farber Cancer Inst · R01 · FY2024 · CA